Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,changeToOperatingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYYNF,27088013,95658600,,,-2419786,,-2419786,1448738,13746,-2465116,-2465116,717335,,,,,0,13746,2478862,0,45330,,-2419786,-2419786,1012833,27088013,2832512,28100846,71816277,3568,-50001028,5272764,2832512,24919567,1012833,5272764,25268334,268816,832537,0.0,7556580.0,7504104.0,5634962.0,167870.0,-2089488.0,69992.0,52476.0,260307.0,,,24255501,en-US,US,EQUITY,False,Delayed Quote,0.0,0.33 - 0.33,0.0,0.0,0.33,0,0,finmb_38323454,Other OTC,Cynata Therapeutics Limited,AUD,1077,3360,0.0,0.0,0.33 - 0.76,-0.42999998,-0.56578946,0.33,0.76,USD,REGULAR,0.33,1629906870,0.0,0.33,0.33,0.33,11120,us_market,4,0,-0.4332421,CYNATA THERAPEUTICS LTD,PNK,-0.04,0.195,0.5069697,-0.17696968,-0.3490735,0.58225924,-0.25225922,31132466,1.6923078,15,America/New_York,EDT,-14400000,False,False,0.46,,,0.76,0.33,0.507,0.5823,1.08k,3.36k,95.66M,,105.8M,14.23%,25.80%,,,,,,,,,,,,,,,,"Jun 29, 2020","Dec 30, 2020",-229.01%,-224.24%,-18.64%,-32.21%,2.59M,0.02,-99.40%,7.01M,-5.53M,-5.93M,-0.0400,,24.92M,0.18,,,24.95,0.19,-5.28M,-2.9M,Value,3053,,"Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",Carlton,61 3 9824 5254,VIC,1609372800,Australia,http://www.cynata.com,86400,62 Lygon Street,61 3 9822 7735,,Level 3
t-1,CYYNF,27088013,95658600,,,-2419786,,-2419786,1448738,13746,-2465116,-2465116,717335,,,,,0,13746,2478862,0,45330,,-2419786,-2419786,1012833,27088013,2832512,28100846,71816277,3568,-50001028,5272764,2832512,24919567,1012833,5272764,25268334,268816,832537,0.0,7556580.0,7504104.0,5634962.0,167870.0,-2089488.0,69992.0,52476.0,260307.0,,,24255501,en-US,US,EQUITY,False,Delayed Quote,0.0,0.33 - 0.33,0.0,0.0,0.33,0,0,finmb_38323454,Other OTC,Cynata Therapeutics Limited,AUD,1077,3360,0.0,0.0,0.33 - 0.76,-0.42999998,-0.56578946,0.33,0.76,USD,REGULAR,0.33,1629906870,0.0,0.33,0.33,0.33,11120,us_market,4,0,-0.4332421,CYNATA THERAPEUTICS LTD,PNK,-0.04,0.195,0.5069697,-0.17696968,-0.3490735,0.58225924,-0.25225922,31132466,1.6923078,15,America/New_York,EDT,-14400000,False,False,0.46,,,0.76,0.33,0.507,0.5823,1.08k,3.36k,95.66M,,105.8M,14.23%,25.80%,,,,,,,,,,,,,,,,"Jun 29, 2020","Dec 30, 2020",-229.01%,-224.24%,-18.64%,-32.21%,2.59M,0.02,-99.40%,7.01M,-5.53M,-5.93M,-0.0400,,24.92M,0.18,,,24.95,0.19,-5.28M,-2.9M,Value,3053,,"Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",Carlton,61 3 9824 5254,VIC,1609372800,Australia,http://www.cynata.com,86400,62 Lygon Street,61 3 9822 7735,,Level 3
t-2,CYYNF,16791104,95658600,2959766.0,,-545219,,-545219,-1886776,1280961,-438111,-438111,518958,,,,,0,1280961,1719071,0,-107110,,-545219,-545219,689736,16791104,2972495,17480840,57165390,3568,-45161456,4787170,3630151,13649644,689736,4787170,13850689,13397,297359,-390456.0,4418525.0,4164405.0,3865715.0,-8.0,-552803.0,70183.0,254120.0,229814.0,6844.0,76032.0,13160953,en-US,US,EQUITY,False,Delayed Quote,0.0,0.33 - 0.33,0.0,0.0,0.33,0,0,finmb_38323454,Other OTC,Cynata Therapeutics Limited,AUD,1077,3360,0.0,0.0,0.33 - 0.76,-0.42999998,-0.56578946,0.33,0.76,USD,REGULAR,0.33,1629906870,0.0,0.33,0.33,0.33,11120,us_market,4,0,-0.4332421,CYNATA THERAPEUTICS LTD,PNK,-0.04,0.195,0.5069697,-0.17696968,-0.3490735,0.58225924,-0.25225922,31132466,1.6923078,15,America/New_York,EDT,-14400000,False,False,0.46,,,0.76,0.33,0.507,0.5823,1.08k,3.36k,95.66M,,105.8M,14.23%,25.80%,,,,,,,,,,,,,,,,"Jun 29, 2020","Dec 30, 2020",-229.01%,-224.24%,-18.64%,-32.21%,2.59M,0.02,-99.40%,7.01M,-5.53M,-5.93M,-0.0400,,24.92M,0.18,,,24.95,0.19,-5.28M,-2.9M,Value,3053,,"Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",Carlton,61 3 9824 5254,VIC,1609372800,Australia,http://www.cynata.com,86400,62 Lygon Street,61 3 9822 7735,,Level 3
t-3,CYYNF,16791104,95658600,2959766.0,,-545219,,-545219,-1886776,1280961,-438111,-438111,518958,,,,,0,1280961,1719071,0,-107110,,-545219,-545219,689736,16791104,2972495,17480840,57165390,3568,-45161456,4787170,3630151,13649644,689736,4787170,13850689,13397,297359,-390456.0,4418525.0,4164405.0,3865715.0,-8.0,-552803.0,70183.0,254120.0,229814.0,6844.0,76032.0,13160953,en-US,US,EQUITY,False,Delayed Quote,0.0,0.33 - 0.33,0.0,0.0,0.33,0,0,finmb_38323454,Other OTC,Cynata Therapeutics Limited,AUD,1077,3360,0.0,0.0,0.33 - 0.76,-0.42999998,-0.56578946,0.33,0.76,USD,REGULAR,0.33,1629906870,0.0,0.33,0.33,0.33,11120,us_market,4,0,-0.4332421,CYNATA THERAPEUTICS LTD,PNK,-0.04,0.195,0.5069697,-0.17696968,-0.3490735,0.58225924,-0.25225922,31132466,1.6923078,15,America/New_York,EDT,-14400000,False,False,0.46,,,0.76,0.33,0.507,0.5823,1.08k,3.36k,95.66M,,105.8M,14.23%,25.80%,,,,,,,,,,,,,,,,"Jun 29, 2020","Dec 30, 2020",-229.01%,-224.24%,-18.64%,-32.21%,2.59M,0.02,-99.40%,7.01M,-5.53M,-5.93M,-0.0400,,24.92M,0.18,,,24.95,0.19,-5.28M,-2.9M,Value,3053,,"Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",Carlton,61 3 9824 5254,VIC,1609372800,Australia,http://www.cynata.com,86400,62 Lygon Street,61 3 9822 7735,,Level 3
